Study Comparing Liquid and Tablet Buprenorphine Formulations - 5

Last updated: November 3, 2005
Sponsor: National Institute on Drug Abuse (NIDA)
Overall Status: Completed

Phase

3

Condition

Opioid Use Disorder

Treatment

N/A

Clinical Study ID

NCT00000302
NIDA-09260-5
P50-09260-5
  • Ages 21-50
  • All Genders

Study Summary

The purpose of this study is to compare liquid and tablet buprenorphine formulations.

Eligibility Criteria

Inclusion

Inclusion Criteria: M/F ages 21-50. Opiate dependence according to DSM-IV criteria. Currently enrolled in theoutpatient protocol comparing liquid and tablet formulations of Buprenorphine. Agreeable toconditions of study and signed informed consent.

Exclusion

Exclusion Criteria: Psychiatric disorder that requires medication therapy. History of seizures. Pregnant and/ornursing women. Dependence on ETOH or benzodiazepines or other sedative-hypnotics. Acutehepatitis. Other medical conditions that deem participation to be unsafe.

Study Design

Study Start date:
Estimated Completion Date:

Study Description

Participants were inducted on either liquid or tablet buprenorphine, in a double-blind, double-dummy manner. They each reached a steady state by the second week, and were scheduled to have blood draws in weeks 3, 4, 7, 8, 11, 12, 15, and 16.

Connect with a study center

  • Friends Research Institute

    Los Angeles, California 90025
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.